ES2403130R1 - Forma polimorfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparacion - Google Patents

Forma polimorfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparacion

Info

Publication number
ES2403130R1
ES2403130R1 ES201290086A ES201290086A ES2403130R1 ES 2403130 R1 ES2403130 R1 ES 2403130R1 ES 201290086 A ES201290086 A ES 201290086A ES 201290086 A ES201290086 A ES 201290086A ES 2403130 R1 ES2403130 R1 ES 2403130R1
Authority
ES
Spain
Prior art keywords
preparation
fexofenadine
polymorphic form
intermediate compounds
chlorhydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201290086A
Other languages
English (en)
Other versions
ES2403130A2 (es
ES2403130B1 (es
Inventor
Marco Baratella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHEMELECTIVA Srl
Original Assignee
CHEMELECTIVA Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHEMELECTIVA Srl filed Critical CHEMELECTIVA Srl
Publication of ES2403130A2 publication Critical patent/ES2403130A2/es
Publication of ES2403130R1 publication Critical patent/ES2403130R1/es
Application granted granted Critical
Publication of ES2403130B1 publication Critical patent/ES2403130B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una nueva forma polimórfica de clorhidrato de fexofenadina, a un procedimiento para prepararla, a composiciones farmacéuticas que la contienen, así como a su uso. La invención también se refiere a compuestos intermedios útiles para la preparación de clorhidrato de fexofenadina, un fármaco antihistamínico usado en el tratamiento de síntomas de alergias.
ES201290086A 2010-06-15 2010-06-15 Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación Expired - Fee Related ES2403130B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2010/000268 WO2011158262A1 (en) 2010-06-15 2010-06-15 Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation

Publications (3)

Publication Number Publication Date
ES2403130A2 ES2403130A2 (es) 2013-05-14
ES2403130R1 true ES2403130R1 (es) 2013-10-04
ES2403130B1 ES2403130B1 (es) 2014-09-29

Family

ID=42732545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201290086A Expired - Fee Related ES2403130B1 (es) 2010-06-15 2010-06-15 Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación

Country Status (3)

Country Link
US (1) US9216955B2 (es)
ES (1) ES2403130B1 (es)
WO (1) WO2011158262A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120329A1 (it) * 2012-03-02 2013-09-03 Chemelectiva S R L Intermedi utili per la sintesi di fexofenadina, processo per la loro preparazione e per la preparazione di fexofenadina
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
EP1260505A1 (en) * 2001-05-17 2002-11-27 Dinamite Dipharma S.p.A. A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
WO2009034582A2 (en) * 2007-09-13 2009-03-19 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
WO1995031437A1 (en) 1994-05-18 1995-11-23 Hoechst Marrion Roussel, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
IN191492B (es) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US20040248935A1 (en) 2001-07-31 2004-12-09 Milla Frederico Junquera Fexofenadine polymorph
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ITMI20041143A1 (it) 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20070987A1 (it) * 2007-05-16 2008-11-17 Dipharma Francis Srl Procedimento per la preparazione di composti chetonici

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
EP1260505A1 (en) * 2001-05-17 2002-11-27 Dinamite Dipharma S.p.A. A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
WO2009034582A2 (en) * 2007-09-13 2009-03-19 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAI, S.H. et al. ¿A Facile Synthesis or an Oxidation Product of Terfenadine¿. Journal of Organic Chemistry 1994, Volumen 59, página 2620-2622. Ver página 2621, esquema 1. *

Also Published As

Publication number Publication date
US9216955B2 (en) 2015-12-22
ES2403130A2 (es) 2013-05-14
ES2403130B1 (es) 2014-09-29
US20130059886A1 (en) 2013-03-07
WO2011158262A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CR20150326A (es) Inhibidores de autotaxina
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
IN2014MN02598A (es)
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
EA201391087A1 (ru) Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
IN2015DN00185A (es)
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY31922A (es) Compuestos
CR20130239A (es) Compuestos de triazolopiridina
CU20110233A7 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
SV2010003725A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA201171414A1 (ru) Ингибиторы белков семейства iap
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2403130

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140929

FD2A Announcement of lapse in spain

Effective date: 20210915